COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlUdwadia (RCT)40%0.60 [0.35-1.02]recov. time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment38%0.62 [0.38-1.02]4/2314/17938% improvementCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Tau​2 = 0.07; I​2 = 49.9%Late treatment28%0.72 [0.52-0.99]121/441129/1,31828% improvementAll studies28%0.72 [0.57-0.92]125/672133/1,49728% improvement9 favipiravir COVID-19 studiesc19favipiravir.com 8/4/211 OT: comparison with other treatmentTau​2 = 0.03; I​2 = 29.6%; Z = 2.65 (p = 0.004)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Dabbous (RCT)45%0.55 [0.05-5.81]1/442/48Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment45%0.55 [0.05-5.81]1/442/4845% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]26/19021/183OT​1Improvement, RR [CI]TreatmentControlAghajani26%0.74 [0.43-1.27]40 (n)951 (n)Tau​2 = 0.00; I​2 = 0.0%Late treatment-7%1.07 [0.67-1.72]26/23021/1,134-7% improvementAll studies-4%1.04 [0.66-1.66]27/27423/1,182-4% improvement3 favipiravir COVID-19 mortality resultsc19favipiravir.com 8/4/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.18 (p = 0.43)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Solaymani-.. (RCT)-19%1.19 [0.73-1.94]31/19025/183OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-19%1.19 [0.73-1.94]31/19025/183-19% improvementAll studies-19%1.19 [0.73-1.94]31/19025/183-19% improvement1 favipiravir COVID-19 ICU resultc19favipiravir.com 8/4/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.72 (p = 0.24)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlDabbous (RCT)16%0.84 [0.67-1.05]hosp. time44 (n)48 (n)Tau​2 = 0.00; I​2 = 0.0%Early treatment16%0.84 [0.67-1.05]3/1562/10416% improvementIvashchenko (RCT)-300%4.00 [0.20-79.6]hosp.2/400/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-300%4.00 [0.20-79.6]2/400/20-300% improvementAll studies15%0.85 [0.68-1.06]5/1962/12415% improvement3 favipiravir COVID-19 hospitalization resultsc19favipiravir.com 8/4/21Tau​2 = 0.00; I​2 = 0.0%; Z = 1.48 (p = 0.07)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlDabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment23%0.77 [0.19-3.18]4/1564/10423% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Improvement, RR [CI]TreatmentControlAghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Tau​2 = 0.00; I​2 = 0.0%Late treatment-7%1.07 [0.67-1.72]26/23021/1,134-7% improvementAll studies-4%1.04 [0.66-1.62]30/38625/1,238-4% improvement4 favipiravir COVID-19 serious outcomesc19favipiravir.com 8/4/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.15 (p = 0.44)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlRuzhentsova (RCT)39%0.61 [0.43-0.88]no recov.112 (n)56 (n)Ruzhentsova (RCT)22%0.78 [0.92-1.79]viral+112 (n)56 (n)Udwadia (RCT)40%0.60 [0.35-1.02]recov. time75 (n)75 (n)Udwadia (RCT)29%0.71 [0.39-1.29]viral time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Dabbous (RCT)88%0.12 [0.01-2.08]ventilation0/444/48Dabbous (RCT)16%0.84 [0.67-1.05]hosp. time44 (n)48 (n)Cai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Cai71%0.29 [0.10-0.86]viral+35 (n)45 (n)Ivashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Ivashchenko (RCT)62%0.38 [0.09-1.52]viral+3/404/20Ivashchenko (RCT)-67%1.67 [0.52-5.39]no disch.10/403/20Ivashchenko (RCT)-300%4.00 [0.20-79.6]hosp.2/400/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Pushkar (RCT)33%0.67 [0.54-0.83]recov. time100 (n)100 (n)Pushkar (RCT)45%0.55 [0.42-0.72]no recov.40/10073/100Pushkar (RCT)20%0.80 [0.61-1.05]recov. time100 (n)100 (n)Pushkar (RCT)70%0.30 [0.16-0.58]no disch.10/10033/100Pushkar (RCT)27%0.73 [0.63-0.86]no recov.66/10090/100Pushkar (RCT)33%0.67 [0.50-0.89]pneumonia40/10060/100Pushkar (RCT)90%0.10 [0.02-0.40]viral+2/10021/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Solaymani-.. (RCT)-53%1.53 [0.86-2.71]ventilation27/19017/183OT​1Solaymani-.. (RCT)-19%1.19 [0.73-1.94]ICU31/19025/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Zhao (RCT)52%0.48 [0.25-0.91]viral time36 (n)19 (n)Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)favipiravir COVID-19 outcomesc19favipiravir.com 8/4/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Molnupiravir
Nitazoxanide
Povidone-Iodine
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Feedback